Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
|Videos|November 5, 2019
Dr Lee Schwartzberg on How Biosimilars Will Help Address Financial Toxicity
We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, or the payer, said Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
Advertisement
We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, or the payer, said Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
Transcript
OneOncology announced that its practices have begun administering the 2 cancer biosimilars on the US market. How will this help address financial toxicity?
We were very proud that OneOncology jumped in as the first group to endorse therapeutic biosimilars in the oncology space. We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, the payer, because you’re giving a high-value drug at a lower cost and therefore across the chain of value, it’s good for everyone. So, there’s education around biosimilars. We’ve been using supportive care biosimilars for a few years.
Some people feel there might be a different bar for therapeutics. I’ve looked at the totality of evidence about what allows a biosimilar to come to market, which is based on a very strong analytic similarity, as well as some clinical trials. We can extrapolate the use of these drugs into the same conditions that we would with the originator drug. I feel very strongly that we’re going to move wholesale into suing biosimilars where there appropriate in the therapeutic oncology space, and it will be great for everyone.
Advertisement
Related to this article
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Tavapadon for Parkinson Disease Approved by FDA
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5